Company intelligence / Profile preview

NovaMatrix

Sandvika, Norway

Ownership: Private
Development stage: Other

Overview

NovaMatrix supplies ultrapure biopolymers such as alginates and hyaluronates for biomedical and pharmaceutical applications. Its products are used in commercially-available medical devices, clinical drug delivery, tissue engineering, and advanced biotechnologies, with established safety and efficacy track records in both preclinical and clinical research contexts[1][2][5][3].

Therapeutic areas: OtherDermatologyRheumatology
Modalities: Hydrogel-based drug delivery therapyCell therapyBiologic
Industry: Chemicals & Materials

Partnerships

Kikkoman Biochemifa Company (Japan, for sodium hyaluronate production)

Beyond the preview

Go deeper on NovaMatrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaMatrix.

Explore the full profile